Results 121 to 130 of about 77,746 (246)

Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. [PDF]

Lancet Respir Med, 2021
Kalil AC, Mehta AK, Patterson TF, Erdmann N, Gomez CA, Jain MK, Wolfe CR, Ruiz-Palacios GM, Kline S, Regalado Pineda J, Luetkemeyer AF, Harkins MS, Jackson PEH, Iovine NM, Tapson VF, Oh MD, Whitaker JA, Mularski RA, Paules CI, Ince D, Takasaki J, Sweeney DA, Sandkovsky U, Wyles DL, Hohmann E, Grimes KA, Grossberg R, Laguio-Vila M, Lambert AA, Lopez de Castilla D, Kim E, Larson L, Wan CR, Traenkner JJ, Ponce PO, Patterson JE, Goepfert PA, Sofarelli TA, Mocherla S, Ko ER, Ponce de Leon A, Doernberg SB, Atmar RL, Maves RC, Dangond F, Ferreira J, Green M, Makowski M, Bonnett T, Beresnev T, Ghazaryan V, Dempsey W, Nayak SU, Dodd L, Tomashek KM, Beigel JH, ACTT-3 study group members.   +56 more
europepmc   +1 more source

Hypofractionated Radiotherapy Induces ISG15+MHC‐I+ Neutrophils to Augment Anti‐Tumor Immunity and Prime Immune Checkpoint Blockade Responses in Rectal Cancer

Advanced Science, EarlyView.
ABSTRACT Our previous clinical trials had demonstrated that neoadjuvant hypofractionated radiotherapy (HFRT) combined with immunotherapy yields promising clinical outcomes in locally advanced rectal cancer (LARC). However, this combined modality benefits only a subset of patients, highlighting the need to uncover the mechanisms underlying how ...
Lichao Liu, Haihong Wang, Mingjie Li, Qian Xu, Linlin Zheng, Chaoqun Han, Zhenwei Zou, Jinghua Ren, Xiaorong Dong, Peng Zhang, Kaixiong Tao, Zhenyu Lin, Tao Zhang   +12 more
wiley   +1 more source

Therapeutic Outcomes of Fingolimod and Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis: A Real-World Study from Jordan. [PDF]

Medicina (Kaunas)
Al Anber A, Abu Al Karsaneh O, Abuquteish D, Abdallah O, Issa MA, Sa'adeh M, Kilani D.   +6 more
europepmc   +1 more source

Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex). [PDF]

CNS Drugs, 2021
Cohan SL, Hendin BA, Reder AT, Smoot K, Avila R, Mendoza JP, Weinstock-Guttman B.   +6 more
europepmc   +1 more source

Macrophage TRIM21 Inhibition Ameliorates Murine Acute Pancreatitis via PHB2‐Mediated Mitochondrial Stabilization

Advanced Science, EarlyView.
Macrophage‐derived TRIM21 drives the progression of AP via ubiquitin‐proteasome‐mediated degradation of PHB2, leading to impaired PHB2‐mediated mitophagy. Therefore, accumulation of cytosolic mtDNA hyperactivates the cGAS‐STING signaling axis, thereby amplifying inflammatory cascades.
Yansong Xu, Yuansong Sun, Xin Zhou, Kai Song, Chunlin Yin, Zhaohua Wang, Fei Xie, He Li   +7 more
wiley   +1 more source

Matching-adjusted indirect comparisons of diroximel fumarate, ocrelizumab and interferon beta-1a for relapsing multiple sclerosis. [PDF]

J Comp Eff Res
Hersh CM, Aladro-Benito Y, Lewin JB, Shen C, Božin I, Sun Z.   +5 more
europepmc   +1 more source

Antagonistic Ubiquitin Switching by USP7 and RNF40 Orchestrates KDM6A Homeostasis to License Coronavirus Susceptibility

Advanced Science, EarlyView.
We identify an antagonistic ubiquitin circuit that controls cellular permissiveness to multiple coronaviruses. The deubiquitinase USP7 stabilizes the epigenetic regulator KDM6A to upregulate viral receptors, while the E3 ligase RNF40 degrades KDM6A by catalyzing K6/K11‐ubiquitin chains of KDM6A for autophagic degradation.
Meng‐Zhuo Huang, Zhong‐Yuan Yang, Shi Wang, Yan Ge, Lan Lin, Mia Madel Alfajaro, Renata B. Filler, Wan‐Yao Song, Ming‐Zhu Kong, Jin Wei   +9 more
wiley   +1 more source

Interferon-beta-1a/natalizumab [PDF]

Reactions Weekly, 2021
openaire   +2 more sources

Outcomes of older patients with multiple sclerosis treated with interferon beta-1a or peginterferon beta-1a in MS PATHS. [PDF]

Neurodegener Dis Manag
Hua LH, Hersh CM, Zhovtis Ryerson L, Belviso N, Vignos M.   +4 more
europepmc   +1 more source

Comparing the outcomes of treatment with INF-β 1-a (interferon beta-1a) and IFN-β 1-b (interferon beta-1b) among COVID-19 inpatients. [PDF]

Int Immunopharmacol, 2021
Seyfi S, Latifi K, Amri Male P, Sadeghi Haddad Zavareh M, Ezoji K, Mohammadnia-Afrozi M.   +5 more
europepmc   +1 more source